

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q83930

Naonori IMAZAKI, et al.

Appln. No.: 10/509,897

Group Art Unit: 1621

Confirmation No.: 1034

Examiner: Shailendra KUMAR

Filed: October 1, 2004

For: BENZAMIDE DERIVATIVES

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. P. Barraclough et al., "Inotropic 2-arylimidazol[1,2- $\alpha$ ]pyrimidines", European of Medical Chemistry, Vol. 27, (1992), pp. 207-217.
2. R.J. De Pasquale et al., "Further Studies on Reactions of Perfluorophenolates with Substituted Pentafluorobenzenes and Perfluorocyclohexene", The Journal of Organic Chemistry, Vol. 33, No. 2, (February 1968), pp. 830-833.
3. U.S. Patent No. 3,478,030 issued November 11, 1969.

4. DE 27 35 919 A1, published February 22, 1979.
5. WO 01/25200 A1, published April 12, 2001 to Takeda Chemical Industries, Ltd.
6. M. Mudrovic, "Studien uber Oxy- und Dioxybiphenyldicarbonsauren Chem Ber.", Vol. 34, Nr. 9, (1913), pp. 1417-1441.
7. DE 24 35 934 A1, published Februar 13, 1975 corresponds to GB 1 455 736.
8. GB 1 455 736 A1, published November 17, 1976.

One copy of each of the listed documents is submitted herewith, except for the following:

U.S. Patent 3,478,030.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Applicant encloses herewith a copy of a corresponding European Examination Report dated December 18, 2007, citing such documents and indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

INFORMATION DISCLOSURE STATEMENT  
U.S. Appln. No.: 10/509,897

Attorney Docket No.: Q83930

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

  
\_\_\_\_\_  
John T. Callahan  
Registration No. 32,607

Date: March ~~24~~ 2008